Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

621 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial.
Aref AA, Scott IU, VanVeldhuisen PC, King J, Ip MS, Blodi BA, Oden NL; Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Investigator Group. Aref AA, et al. JAMA Ophthalmol. 2021 Dec 1;139(12):1285-1291. doi: 10.1001/jamaophthalmol.2021.4395. JAMA Ophthalmol. 2021. PMID: 34709363 Free PMC article. Clinical Trial.
Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.
Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA; SCORE2 Study Investigator Group. Scott IU, et al. JAMA Ophthalmol. 2022 May 1;140(5):458-464. doi: 10.1001/jamaophthalmol.2022.0352. JAMA Ophthalmol. 2022. PMID: 35323843 Free PMC article. Clinical Trial.
Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration in Vulnerable Fellow Eyes: A Randomized Clinical Trial.
Chan CK, Lalezary M, Abraham P, Elman M, Beaulieu WT, Lin SG, Khurana RN, Bansal AS, Wieland MR, Palmer JD, Chang LK, Lujan BJ, Yiu G; PREVENT Study Group. Chan CK, et al. Among authors: palmer jd. Ophthalmol Retina. 2022 Jun;6(6):484-494. doi: 10.1016/j.oret.2022.01.019. Epub 2022 Feb 1. Ophthalmol Retina. 2022. PMID: 35121216 Clinical Trial.
SLC16A8 is a causal contributor to age-related macular degeneration risk.
Nouri N, Gussler BH, Stockwell A, Truong T, Kang GJ, Browder KC, Malato Y, Sene A, Van Everen S, Wykoff CC, Brown D, Fu A, Palmer JD, Lima de Carvalho JR, Ullah E, Al Rawi R, Chew EY, Zein WM, Guan B, McCarthy MI, Hofmann JW, Chaney SY, Jasper H, Yaspan BL. Nouri N, et al. Among authors: palmer jd. NPJ Genom Med. 2024 Oct 28;9(1):50. doi: 10.1038/s41525-024-00442-8. NPJ Genom Med. 2024. PMID: 39468037 Free PMC article.
621 results